share_log

Azitra | 8-K: Current report

Azitra | 8-K: Current report

Azitra | 8-K:重大事件
美股SEC公告 ·  2024/08/13 05:17

牛牛AI助理已提取核心訊息

Azitra reported Q2 2024 financial results and provided pipeline updates. Revenue was $7,500, down from $172,000 in Q2 2023. R&D expenses increased to $1.1M from $0.8M YoY, while G&A expenses rose to $1.5M from $0.8M. Net loss narrowed to $2.6M from $5.1M. Cash position was $0.8M as of June 30, 2024.The company completed a $10M follow-on offering, extending cash runway into 2025. Key upcoming milestones include dosing the first Netherton syndrome patient with ATR-12 in Q3 2024, filing an IND for ATR-04 in EGFRi rash, and initiating its first-in-human trial by year-end. Azitra expects to report initial ATR-12 safety data and provide a Bayer license agreement update by year-end 2024.CEO Francisco Salva expressed confidence in achieving significant milestones in H2 2024 and beyond. The company anticipates reporting topline data from the ATR-12 Phase 1b trial in Netherton syndrome by mid-2025, aiming to demonstrate proof of concept for its innovative approach to this rare skin disorder.
Azitra reported Q2 2024 financial results and provided pipeline updates. Revenue was $7,500, down from $172,000 in Q2 2023. R&D expenses increased to $1.1M from $0.8M YoY, while G&A expenses rose to $1.5M from $0.8M. Net loss narrowed to $2.6M from $5.1M. Cash position was $0.8M as of June 30, 2024.The company completed a $10M follow-on offering, extending cash runway into 2025. Key upcoming milestones include dosing the first Netherton syndrome patient with ATR-12 in Q3 2024, filing an IND for ATR-04 in EGFRi rash, and initiating its first-in-human trial by year-end. Azitra expects to report initial ATR-12 safety data and provide a Bayer license agreement update by year-end 2024.CEO Francisco Salva expressed confidence in achieving significant milestones in H2 2024 and beyond. The company anticipates reporting topline data from the ATR-12 Phase 1b trial in Netherton syndrome by mid-2025, aiming to demonstrate proof of concept for its innovative approach to this rare skin disorder.
Azitra報告了2024年第二季度的財務結果並提供了管道更新。營業收入爲7500美元,較2023年第二季度的172,000美元下降。研發費用同比增加至110萬,管理費用上升至150萬,均較去年增加,而淨虧損縮小至260萬,較510萬的虧損有所減少。到2024年6月30日,現金狀況爲80萬。公司完成了一項1000萬的後續融資,現金跑道延長至2025年。即將到來的關鍵里程碑包括在2024年第三季度爲第一位Netherton綜合症患者使用ATR-12用藥,針對EGFRi皮疹提交IND申請,並在年底前啓動首個人體試驗。Azitra預計將在2024年年末報告初步ATR-12安全性數據,並提供拜耳許可協議的更新。首席執行官Francisco Salva對在2024年下半年及以後實現重大里程碑表達了信心。公司預計在2025年中旬報告來自ATR-12階段10億試驗的初步數據,旨在展示其對這一罕見皮膚病的新創新方法的概念驗證。
Azitra報告了2024年第二季度的財務結果並提供了管道更新。營業收入爲7500美元,較2023年第二季度的172,000美元下降。研發費用同比增加至110萬,管理費用上升至150萬,均較去年增加,而淨虧損縮小至260萬,較510萬的虧損有所減少。到2024年6月30日,現金狀況爲80萬。公司完成了一項1000萬的後續融資,現金跑道延長至2025年。即將到來的關鍵里程碑包括在2024年第三季度爲第一位Netherton綜合症患者使用ATR-12用藥,針對EGFRi皮疹提交IND申請,並在年底前啓動首個人體試驗。Azitra預計將在2024年年末報告初步ATR-12安全性數據,並提供拜耳許可協議的更新。首席執行官Francisco Salva對在2024年下半年及以後實現重大里程碑表達了信心。公司預計在2025年中旬報告來自ATR-12階段10億試驗的初步數據,旨在展示其對這一罕見皮膚病的新創新方法的概念驗證。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。